Qualifications

• American Society of Genitourinary Oncology Certification,  American Urological Association

• Fellow of Royal Australasian College of Surgeons (FRACS Urology) 

• Doctor of Medicine (M.D. Thesis), University of Auckland

• Bachelor of Medicine and Bachelor of Surgery (MBChB) University of Otago

Book Chapters

• Zargar-Shoshtari K, Kovitz, C., Spiess, P., Tannir, N. Testicular Germ Cell Tumors,  Encyclopedia of Cancer (4th edition), Schwab, Manfred (Ed.) Springer Publications, 2016, ISBN 978-3-662-47424-2

• Zargar-Shoshtari K, Sharma P, Spiess PE. Primary Urethral Carcinoma, Rare Urological Malignancies, (Editor: L. Pagliaro) Springer International Publishing Switzerland. 2016, (pp153-161), ISBN 978-3-319-30046-7

• Sharma P, Zargar-Shoshtari K, Pow-Sang JM. Ilioinguinal Lymphadenectomy. In: Hinman’s Atlas of Urologic Surgery, 4th Ed (Editors: Dr. Joseph A. Smith, Jr. Stuart S. Howards, Glenn M. Preminger, and Roger R. Dmochowski) (In Press– January 2016).

• Sharma P, Zargar-Shoshtari K, Zargar H, Spiess PE. Pelvic Lymph Node Dissection for Penile Cancer: Answering the Conundrum of When and How It Should Be Conducted. In ­­­­­Penile Cancer 2017 (pp. 81-92). Springer, New York.

Journal Articles 

1.            van Breugel SJ, Low I, Christie ML, Pokorny MR, Nagarajan R, Holtkamp HU, Zargar-Shoshtari K et al. Raman spectroscopy system for real-time diagnosis of clinically significant prostate cancer tissue. J Biophotonics. 2023;16(5):e202200334.

2.            Rashid P, Zargar-Shoshtari K, Ranasinghe W. Prostate-specific antigen testing for prostate cancer: Time to reconsider the approach to screening. Aust J Gen Pract. 2023;52(3):91-5.

3.            Chao PP, Koea JB, Zargar-Shoshtari K, Du J, Hill AG, Srinivasa S. Robot-assisted radical prostatectomy in Aotearoa New Zealand: equity, quality, and workforce. ANZ J Surg. 2023;93(12):2789-91.

4.            Kazemzadeh M, Hisey CL, Zargar-Shoshtari K, Xu W, Broderick NG. Deep convolutional neural networks as a unified solution for Raman spectroscopy-based classification in biomedical applications. Optics Communications. 2022:127977.

5.            Kazemzadeh M, Hisey CL, Dauros-Singorenko P, Swift S, Zargar-Shoshtari K, Xu W, et al. Label-free classification of bacterial extracellular vesicles by combining nanoplasmonic sensors with machine learning. IEEE Sensors Journal. 2022;22(2):1128-37.

6.            D'Andrea D, Black PC, Zargar H, Dinney CP, Soria F, Cookson MS, et al. Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder Cancer. Journal of Urology. 2022;207(1):70-6.

7.            Mir MC, Marchioni M, Zargar H, Zargar-Shoshtari K, Fairey A, Mertens LS, et al. Nomogram predicting bladder cancer–specific mortality after neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer: results of an international consortium. European urology focus. 2021;7(6):1347-54.

8.            Matti B, Zargar-Shoshtari K. Age-adjusted reference values for prostate-specific antigen in a multi-ethnic population. Int J Urol. 2021;28(5):578-83.

9.            Matti B, Zargar-Shoshtari K. Prostate cancer outcomes disparities: Population survival analysis in an ethnically diverse nation. Urol Oncol. 2021;39(6):367 e19- e26.

10.         Matti B, Xia W, van der Werf B, Zargar-Shoshtari K. Age-Adjusted Reference Values for Prostate Specific Antigen - A Systematic Review and Meta-Analysis. Clin Genitourin Cancer. 2021.

11.         Matti B, Reeves F, Prouse M, Zargar-Shoshtari K. The impact of the extent and location of positive surgical margins on the risk of biochemical recurrence following radical prostatectomy in men with Gleason 7 prostate cancers. Prostate. 2021;81(16):1428-34.

12.         Matti B, Lyndon M, Zargar-Shoshtari K. Ethnic and socio-economic disparities in prostate cancer screening: lessons from New Zealand. BJU Int. 2021;128 Suppl 3:11-7.

13.         Matti B, Chapman D, Zargar-Shoshtari K. Ethnic and regional differences in the temporal trends of prostate cancer incidence and mortality in New Zealand. ANZ J Surg. 2021;91(12):2806-16.

14.         Mark S, Rashid P, Heathcote P, Zargar Shoshtari K. Differences in treatment choices for localised prostate cancer diagnosed in private and public health services. Med J Aust. 2021;214(10):485- e1.

15.         Kazemzadeh M, Hisey CL, Artuyants A, Blenkiron C, Chamley LW, Zargar-Shoshtari K, et al. Space curvature-inspired nanoplasmonic sensor for breast cancer extracellular vesicle fingerprinting and machine learning classification. Biomed Opt Express. 2021;12(7):3965-81.

16.         D'Andrea D, Black PC, Zargar H, Zargar-Shoshtari K, Soria F, Fairey AS, et al. Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer. World J Urol. 2021;39(12):4345-54.

17.         Bajaj M, Smith R, Rice M, Zargar-Shoshtari K. Predictors of success following extracorporeal shock-wave lithotripsy in a contemporary cohort. Urol Ann. 2021;13(3):282-7.

18.         Matti B, Zargar-Shoshtari K. Prostate cancer screening in New Zealand: lessons from the past to shape the future in the light of changing evidence. N Z Med J. 2020;133(1523):87-95.

19.         Matti B, Zargar-Shoshtari K. Opportunistic prostate cancer screening: A population-based analysis. Urol Oncol. 2020;38(5):393-400.

20.         Matthews SJ, Tyson M, Lauti M, Zargar K. Sexually transmitted infective vasitis mimicking left inguinal hernia: computed tomography clarifies diagnosis. Anz Journal of Surgery. 2020:2.

21.         D'Andrea D, Black PC, Zargar H, Zargar-Shoshtari K, Zehetmayer S, Fairey AS, et al. Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer. Urol Oncol Semin Orig Invest. 2020.

22.         Black AJ, Zargar H, Zargar-Shoshtari K, Fairey AS, Mertens LS, Dinney CP, et al. The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy. Urologic Oncology-Seminars and Original Investigations. 2020;38(1).

23.         Rudzinski JK, Carlock HR, Beech BB, Zargar-Shoshtari K, Sharma P, Kim T, et al. Empty hemiscrotum and a giant abdominal mass case report. AME Medical Journal. 2019;4.

24.         Ottenhof SR, Leone A, Djajadiningrat RS, Azizi M, Zargar K, Kidd LC, et al. Surgical and Oncological Outcomes in Patients After Vascularised Flap Reconstruction for Locoregionally Advanced Penile Cancer. European Urology Focus. 2019;5(5):867-74.

25.         Zargar-Shoshtari K, Sharma P, Spiess PE. Insight into novel biomarkers in penile cancer: Redefining the present and future treatment paradigm? Urologic Oncology-Seminars and Original Investigations. 2018;36(10):433-9.

26.         Zargar-Shoshtari K, Sexton WJ. Re: Stenting Prior to Cystectomy is an Independent Risk Factor for Upper Urinary Tract Recurrence. Journal of Urology. 2018;200(2):457-.

27.         Ong WM, Zargar-Shoshtari K, Siva S, Zargar H. Prostate specific membrane antigen: the role in salvage lymph node dissection and radio-ligand therapy. Minerva Urol Nefrol. 2018;70(5):450-61.

28.         Chipollini J, Abel EJ, Peyton CC, Boulware DC, Karam JA, Margulis V, et al. Pathologic Predictors of Survival During Lymph Node Dissection for Metastatic Renal-Cell Carcinoma: Results From a Multicenter Collaboration. Clinical Genitourinary Cancer. 2018;16(2):E443-E50.

29.         Bajaj M, Yuan L, Holmes LC, Rice M, Zargar-Shoshtari K. Predictors of surgical intervention following initial surveillance for acute ureteric colic. World Journal of Urology. 2018;36(9):1477-83.

30.         Zargar-Shoshtari K, Murphy DG, Zargar H. Re: Robot-assisted Laparoscopic Prostatectomy Versus Open Radical Retropubic Prostatectomy: Early Outcomes from a Randomised Controlled Phase 3 Study. European Urology. 2017;71(1):140-1.

31.         Zargar-Shoshtari K, Lawrentschuk N, Zargar H. Robotic Prostatectomy Delivers on the Promise of Minimally Invasive Surgery Commentary on: Robot-assisted Laparoscopic Prostatectomy Versus Open Radical Retropubic Prostatectomy: Early Outcomes from a Randomised Controlled Phase 3 Study. Urology. 2017;99:3-4.

32.         Zargar-Shoshtari K, Hill AG. Surgical research in the public hospital. Anz Journal of Surgery. 2017;87(6):428-9.

33.         Zargar H, Shah JB, van de Putte EEF, Potvin KR, Zargar-Shoshtari K, van Rhijn BW, et al. Dose dense MVAC prior to radical cystectomy: a real-world experience. World Journal of Urology. 2017;35(11):1729-36.

34.         Sharma P, Zargar-Shoshtari K, Poch MA, Pow-Sang JM, Sexton WJ, Spiess PE, et al. Surgical control and margin status after robotic and open cystectomy in high-risk cases: Caution or equivalence? World Journal of Urology. 2017;35(4):657-63.

35.         Nair R, Zargar-Shoshtari K, Zargar H. Bridging the gap: use of scaffolding tissue bio-grafts to bolster vesicourethral anastomosis during salvage robot-assisted prostatectomy reduced leak rates and catheter times. Translational Andrology and Urology. 2017;6(3):595-6.

36.         Leone AR, Zargar-Shoshtari K, Diorio GJ, Sharma P, Boulware D, Gilbert SM, et al. Neoadjuvant Chemotherapy in Elderly Patients With Bladder Cancer: Oncologic Outcomes From a Single Institution Experience. Clinical Genitourinary Cancer. 2017;15(4):E583-E9.

37.         Leone AR, Kidd LC, Diorio GJ, Zargar-Shoshtari K, Sharma P, Sexton WJ, et al. Bilateral benign renal oncocytomas and the role of renal biopsy: single institution review. Bmc Urology. 2017;17.

38.         Abel EJ, Spiess PE, Margulis V, Master VA, Mann M, Zargar-Shoshtari K, et al. Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus. Journal of Urology. 2017;198(2):281-8.

39.         Zargar-Shoshtari K, Zargar H, Lotan Y, Shah JB, van Rhijn BW, Daneshmand S, et al. A Multi-Institutional Analysis of Outcomes of Patients with Clinically Node Positive Urothelial Bladder Cancer Treated with Induction Chemotherapy and Radical Cystectomy. Journal of Urology. 2016;195(1):53-9.

40.         Zargar-Shoshtari K, Zargar H, Dinney CP, Ercole CE, Sharma P, Kovac E, et al. Clinical and therapeutic factors associated with adverse pathological outcomes in clinically node-negative patients treated with neoadjuvant cisplatin-based chemotherapy and radical cystectomy. World Journal of Urology. 2016;34(5):695-701.

41.         Zargar-Shoshtari K, Sverrisson EF, Sharma P, Gupta S, Poch MA, Pow-Sang JM, et al. Clinical Outcomes After Neoadjuvant Chemotherapy and Radical Cystectomy in the Presence of Urothelial Carcinoma of the Bladder With Squamous or Glandular Differentiation. Clinical Genitourinary Cancer. 2016;14(1):82-8.

42.         Zargar-Shoshtari K, Spiess PE, Berglund AE, Sharma P, Powsang JM, Giuliano A, et al. Clinical Significance of p53 and p16(ink4a) Status in a Contemporary North American Penile Carcinoma Cohort. Clinical Genitourinary Cancer. 2016;14(4):346-51.

43.         Zargar-Shoshtari K, Sharma P, Djajadiningrat R, Catanzaro M, Ye DW, Zhu Y, et al. Extent of pelvic lymph node dissection in penile cancer may impact survival. World Journal of Urology. 2016;34(3):353-9.

44.         Zargar-Shoshtari K, Sharma P, Djajadiningrat R. Bilaterale Lymphadenektomie trotz unilateraler Metastasen? Urologie Scan. 2016;3(03):204-.

45.         Zargar-Shoshtari K, Sexton WJ, Poch MA. Management of Urethral Recurrences Urothelial and Nonurothelial. Urol Clin North Am. 2016;43(4):515-+.

46.         Zargar-Shoshtari K, Kongnyuy M, Sharma P, Fishman MN, Gilbert SM, Poch MA, et al. Clinical role of additional adjuvant chemotherapy in patients with locally advanced urothelial carcinoma following neoadjuvant chemotherapy and cystectomy. World Journal of Urology. 2016;34(11):1567-73.

47.         Zargar-Shoshtari K, Ashouri K, Sharma P, Baumgarten A, Sexton WJ, Pow-Sang J, et al. Nephrectomy and inferior vena cava thrombectomy for renal cell carcinoma among patients with impaired renal function: defining predictors of outcomes. Anz Journal of Surgery. 2016;86(1-2):44-8.

48.         Zargar H, Zargar-Shoshtari K, Lotan Y, Shah JB, van Rhijn BW, Daneshmand S, et al. Final Pathological Stage after Neoadjuvant Chemotherapy and Radical Cystectomy for Bladder Cancer-Does pT0 Predict Better Survival than pTa/Tis/T1? Journal of Urology. 2016;195(4):886-91.

49.         Zargar H, Zargar-Shoshtari K, Dundee P, Black PC. Predicting occult lymph node-positive disease at the time of radical cystectomy: a systematic review. Minerva Urol Nefrol. 2016;68(2):112-24.

50.         Zargar H, Atwell TD, Cadeddu JA, de la Rosette JJ, Janetschek G, Kaouk JH, Zargar-Shoshtari K et al. Cryoablation for Small Renal Masses: Selection Criteria, Complications, and Functional and Oncologic Results. European Urology. 2016;69(1):116-28.

51.         Singh PP, Su'a B, Hill AG, Zargar-Shoshtari K. Peritoneal Cytokine Levels Can Predict Anastomotic Leak on the First Postoperative Day (vol 59, pg 551, 2016). Diseases of the Colon & Rectum. 2016;59(8):724-.

52.         Sharma P, Zargar-Shoshtari K, Spiess PE, Sexton WJ, Poch MA. Undiagnosed prostatic malignancy at the time of radical cystoprostatectomy after prior prostatic radiation therapy. Urology Annals. 2016;8(2):151-6.

53.         Sharma P, Zargar-Shoshtari K, Pow-Sang JM. Biomarkers for prostate cancer: present challenges and future opportunities. Futur Sci OA. 2016;2(1).

54.         Sharma P, Zargar-Shoshtari K, Pettaway CA, Schabath MB, Giuliano AR, Spiess PE. Disparities in Penile Cancer. Cancer Control. 2016;23(4):409-14.

55.         Sharma P, McCormick BZ, Zargar-Shoshtari K, Sexton WJ. Is surgeon intuition equivalent to models of operative complexity in determining the surgical approach for nephron sparing surgery? Indian Journal of Urology. 2016;32(2):124-31.

56.         Sharma P, Henriksen CH, Zargar-Shoshtari K, Xin R, Poch MA, Pow-Sang JM, et al. Preoperative Patient Reported Mental Health is Associated with High Grade Complications after Radical Cystectomy. Journal of Urology. 2016;195(1):47-52.

57.         Sharma P, Ashouri K, Zargar-Shoshtari K, Luchey AM, Spiess PE. Racial and economic disparities in the treatment of penile squamous cell carcinoma: Results from the National Cancer Database. Urologic Oncology-Seminars and Original Investigations. 2016;34(3).

58.         Sammour T, Singh PP, Zargar-Shoshtari K, Su'a B, Hill AG. Peritoneal Cytokine Levels Can Predict Anastomotic Leak on the First Postoperative Day. Diseases of the Colon & Rectum. 2016;59(6):551-6.

59.         Leone A, Diorio G, Zargar-Shoshtari K, Spiess PE. Comprehensive characterization of the perioperative morbidity of cytoreductive nephrectomy. Translational Andrology and Urology. 2016;5(3):393-5.

60.         Leone A, Diorio G, Brito J, Zargar K, Pareek G, Renzulli JF, et al. Presence and percentage of type 2 papillary RCC in mixed (type 1 and type 2) papillary renal cell carcinoma does not portend worse prognosis in patients treated by partial/radical nephrectomy in non-metastatic disease. Journal of Clinical Oncology. 2016;34(15).

61.         Acland G, Zargar-Shoshtari K, Rice M. Contemporary trends in urinary tract stone surgery, a regional perspective: Auckland, New Zealand. Anz Journal of Surgery. 2016;86(4):244-8.

62.         Zargar-Shoshtari K, Zargar H, Fairey AS, Mertens LS, Dinney CP, Mir MC, et al. A MULTI-INSTITUTIONAL ANALYSIS OF OUTCOMES IN PATIENTS WITH CLINICALLY NODE POSITIVE UROTHELIAL BLADDER CANCER TREATED WITH INDUCTION CHEMOTHERAPY AND RADICAL CYSTECTOMY. Journal of Urology. 2015;193(4):E809-E.

63.         Zargar-Shoshtari K, Zargar H, Dinney CP, Ercole CE, Abdi H, Kovac E, et al. CLINICAL FACTORS PREDICTING PATHOLOGICAL POSITIVE LYMPH NODES IN CLINICALLY NODE NEGATIVE PATIENTS TREATED WITH NEOADJUVANT CHEMOTHERAPY AND RADICAL CYSTECTOMY. Journal of Urology. 2015;193(4):E702-E.

64.         Zargar-Shoshtari K, Sharma P, Zargar H. Re: Medical Expulsive Therapy in Adults with Ureteric Colic: A Multicentre, Randomised, Placebo-controlled Trial. European Urology. 2015;68(5):910-1.

65.         Zargar-Shoshtari K, Sharma P, Spiess PE. Re: Oliver W. Hakenberg, Eva M. Comperat, Suks Minhas, Andrea Necchi, Chris Protzel, Nick Watkin. EAU Guidelines on Penile Cancer: 2014 Update. Eur Urol 2015; 67: 142-50. European Urology. 2015;67(6):E109-E10.

66.         Zargar-Shoshtari K, Sharma P, Pow-Sang J. Salvage Therapies for Radiorecurrent Prostate Cancer. Urology Practice. 2015;2(3):126-32.

67.         Zargar-Shoshtari K, Sharma P, Espiritu P, Kurian T, Pow-Sang JM, Mangar D, et al. Caval tumor thrombus volume influences outcomes in renal cell carcinoma with venous extension. Urologic Oncology-Seminars and Original Investigations. 2015;33(3).

68.         Zargar-Shoshtari K, Kim T, Simon R, Sharma P, Yue BL, Lin HY, et al. IS FOLLOW UP BEYOND 2 YEARS NECESSARY FOR PT1A RENAL CELL CARCINOMA TREATED WITH NEPHRON SPARING SURGERY? AN ASSESSMENT OF LATE RECURRENCES AND SURVEILLANCE COSTS. Journal of Urology. 2015;193(4):E611-E.

69.         Zargar-Shoshtari K, Kim T, Simon R, Lin HY, Yue BL, Sharma P, et al. Surveillance Following Nephron-Sparing Surgery: An Assessment of Recurrence Patterns and Surveillance Costs. Urology. 2015;86(2):321-6.

70.         Zargar-Shoshtari K, Djajadiningrat R, Sharma P, Catanzaro M, Zhu Y, Nicolai N, et al. Establishing Criteria for Bilateral Pelvic Lymph Node Dissection in the Management of Penile Cancer: Lessons Learned from an International Multicenter Collaboration. Journal of Urology. 2015;194(3):696-701.

71.         Zargar-Shoshtari K, Anderson W, Rice M. Role of emergency ureteroscopy in the management of ureteric stones: analysis of 394 cases. Bju International. 2015;115(6):946-50.

72.         Zargar H, Zargar-Shoshtari K, Laydner H, Autorino R. Anatomy of Contemporary Partial Nephrectomy: A Dissection of the Available Evidence. European Urology. 2015;68(6):993-5.

73.         Zargar H, Zargar-Shoshtari K, Fairey AS, Mertens LS, Dinney CP, Mir MC, et al. FINAL PATHOLOGIC STAGE AFTER NEOADJUVANT CHEMOTHERAPY AND RADICAL CYSTECTOMY FOR BLADDER CANCER: DOES PT0 PREDICT BETTER SURVIVAL THAN PTA/PTIS/PT1? Journal of Urology. 2015;193(4):E841-E.

74.         Xylinas E, Zargar-Shoshtari K, Shah J, Zargar H, Fairey A, Mertens L, et al. THE INTERVAL BETWEEN DIAGNOSIS AND RADICAL CYSTECTOMY DOES NOT IMPACT THE OUTCOMES OF PATIENTS TREATED WITH NEOADJUVANT CHEMOTHERAPY. Journal of Urology. 2015;193(4):E926-E7.

75.         Sharma P, Zargar-Shoshtari K, Spiess PE. Current surgical management of penile cancer. Current Problems in Cancer. 2015;39(3):147-57.

76.         Sharma P, Zargar-Shoshtari K, Sexton WJ. Valrubicin in refractory non-muscle invasive bladder cancer. Expert Review of Anticancer Therapy. 2015;15(12):1379-87.

77.         Sharma P, Zargar-Shoshtari K, Caracciolo JT, Richard GJ, Poch MA, Pow-Sang J, et al. Sarcopenia as a predictor of complications in penile cancer patients undergoing inguinal lymph node dissection. World Journal of Urology. 2015;33(10):1585-92.

78.         Sharma P, Zargar-Shoshtari K, Caracciolo J, Fishman M, Poch M, Pow-Sang J, et al. SARCOPENIA AS A PREDICTOR OF SURVIVAL AFTER CYTOREDUCTIVE NEPHRECTOMY FOR METASTATIC RENAL CELL CARCINOMA. Journal of Urology. 2015;193(4):E733-E.

79.         Sharma P, Sverrisson EF, Zargar-Shoshtari K, Fishman MN, Sexton WJ, Dickinson SI, et al. Minimally invasive post-chemotherapy retroperitoneal lymph node dissection for nonseminoma. Canadian Journal of Urology. 2015;22(4):7882-9.

80.         Sharma P, Djajadiningrat R, Zargar-Shoshtari K, Catanzaro M, Zhu Y, Nicolai N, et al. Adjuvant chemotherapy is associated with improved overall survival in pelvic node-positive penile cancer after lymph node dissection: A multi-institutional study. Urologic Oncology-Seminars and Original Investigations. 2015;33(11).

81.         Sharma P, Djajadiningrat R, Zargar-Shoshtari K, Catanzaro M, Zhu Y, Nicolai N, et al. PELVIC EXTRANODAL EXTENSION LEADS TO WORSE OUTCOMES IN PENILE CANCER PATIENTS WITH POSITIVE PELVIC LYMPH NODES AND IS ASSOCIATED WITH A SURVIVAL BENEFIT AFTER ADJUVANT CHEMOTHERAPY: A MULTI-INSTITUTIONAL STUDY. Journal of Urology. 2015;193(4):E115-E.

82.         Sharma P, Dhillon J, Agarwal G, Zargar-Shoshtari K, Sexton WJ. Disparities in Interpretation of Primary Testicular Germ Cell Tumor Pathology. American Journal of Clinical Pathology. 2015;144(2):289-94.

83.         Kim T, Zargar-Shoshtari K, Dhillon J, Lin HY, Yue BL, Fishman M, et al. Using Percentage of Sarcomatoid Differentiation as a Prognostic Factor in Renal Cell Carcinoma. Clinical Genitourinary Cancer. 2015;13(3):225-30.

84.         Singh PP, Srinivasa S, Bambarawana S, Lemanu DP, Kahokehr AA, Zargar-Shoshtari K, et al. Perioperative Use of Statins in Elective Colectomy. Diseases of the Colon & Rectum. 2012;55(2):205-10.

85.         Sammour T, Kahokehr A, Zargar-Shoshtari K, Hill AG. A Prospective Case-Control Study of the Local and Systemic Cytokine Response After Laparoscopic Versus Open Colonic Surgery. Journal of Surgical Research. 2012;173(2):278-85.

86.         Lemanu D, Srinivasa S, Singh P, Kahokehr A, Zargar-Shoshtari K, Hill AG. Propensity score analysis evaluating preoperative glucocorticoid administration in elective colectomy. International Journal of Surgery. 2012;10(10):607-10.

87.         Paddison JS, Sammour T, Kahokehr A, Zargar-Shoshtari K, Hill AG. Development and Validation of the Surgical Recovery Scale (SRS). Journal of Surgical Research. 2011;167(2):E85-E91.

88.         Kahokehr AA, Zargar-Shoshtari K, Sammour T, Srinivasa S, Hill AG. Fatigue postopératoire: mythe ou réalité. Le Praticien en anesthésie réanimation. 2011;15(1):35-9.

89.         Kahokehr AA, Sammour T, Sahakian V, Zargar-Shoshtari K, Hill AG. Influences on length of stay in an enhanced recovery programme after colonic surgery. Colorectal Disease. 2011;13(5):594-9.

90.         Kahokehr A, Sammour T, Shoshtari KZ, Taylor M, Hill AG. Intraperitoneal Local Anesthetic Improves Recovery After Colon Resection A Double-Blinded Randomized Controlled Trial. Ann Surg. 2011;254(1):28-38.

91.         Kahokehr A, Sammour T, Zargar-Shoshtari K, Srinivasa S, Hill AG. Recovery After Open and Laparoscopic Right Hemicolectomy: A Comparison. Journal of Surgical Research. 2010;162(1):11-6.

92.         Zargar-Shoshtari K, Sammour T, Kahokehr A, Connolly AB, Hill AG. Randomized clinical trial of the effect of glucocorticoids on peritoneal inflammation and postoperative recovery after colectomy. British Journal of Surgery. 2009;96(11):1253-61.

93.         Zargar-Shoshtari K, Paddison JS, Booth RJ, Hill AG. A Prospective Study on the Influence of a Fast-Track Program on Postoperative Fatigue and Functional Recovery After Major Colonic Surgery. Journal of Surgical Research. 2009;154(2):330-5.

94.         Zargar-Shoshtari K, Hill AG. Postoperative Fatigue: A Review. World Journal of Surgery. 2009;33(4):738-47.

95.         Vather R, Sammour T, Zargar-Shoshtari K, Metcalf P, Connolly A, Hill A. Lymph node examination as a predictor of long-term outcome in Dukes B colon cancer. International Journal of Colorectal Disease. 2009;24(3):283-8.

96.         Shoshtari KZ, Hill AG. Fast-Track Surgery May Reduce Complications Following Major Colonic Surgery Reply. Diseases of the Colon & Rectum. 2009;52(10):1804-5.

97.         Shoshtari KZ. Multimodal Interventions for Improving Convalescence Following Major Colonic Surgery: Doctoral dissertation, Medicine in Surgery, Faculty of Medicine, University …; 2009.

98.         Kahokehr A, Sammour T, Zargar-Shoshtari K, Thompson L, Hill AG. Implementation of ERAS and how to overcome the barriers. International Journal of Surgery. 2009;7(1):16-9.

99.         Zargar-Shoshtari K, Short H, Poole GH, Hill AG. Acute laparoscopic cholecystectomy: Preferred treatment for acute biliary disease. Anz Journal of Surgery. 2008;78(9):771-4.

100.       Zargar-Shoshtari K, Hill AG. Optimization of perioperative care for colonic surgery: A review of the evidence. Anz Journal of Surgery. 2008;78(1-2):13-23.

101.       Zargar-Shoshtari K, Connolly AB, Israel LH, Hill AG. Fast-Track Surgery May Reduce Complications Following Major Colonic Surgery. Diseases of the Colon & Rectum. 2008;51(11):1633-40.

102.       SHOSHTARI KZ, CONNOLLY A, ISRAEL L, CLARK M, HILL A. ONE YEAR EXPERIENCE WITH FAST-TRACK SURGERY FOR ELECTIVE COLONIC RESECTION: CR08. Anz Journal of Surgery. 2007;77.

103.       Vather R, Zargar-Shoshtari K, Adegbola S, Hill AG. Comparison of the POSSUM, P-POSSUM and Cr-POSSUM scoring systems as predictors of postoperative mortality in patients undergoing major colorectal surgery. Anz Journal of Surgery. 2006;76(9):812-6.

104.       Vather R, Shoshtari K, Ducat C, Hill A. Towards a 3-day hospital stay for right hemicolectomy. The New Zealand Medical Journal (Online). 2006;119(1228).

105.       Shahrokh H, Rasouli H, Zargar M, Karimi K, Zargar K, editors. Spontaneous kidney allograft rupture. Transplantation proceedings; 2005: Elsevier.